An international consortium led by ATRO Medical, a spin-off of Radboudumc and DSM, will receive € 800,000 European funding for an innovation aimed at patients with knee osteoarthritis. These patients often suffer from cartilage wear due to a meniscus that no longer works properly. The consortium, which further consists of the Orthopaedic Research Laboratory (ORL) of the Radboudumc and the Swiss company Samaplast, will develop the first sustainable meniscus prosthesis to replace the outer meniscus.
Knee osteoarthritis is one of the major causes of disability worldwide. Loss of meniscus tissue in young years can accelerate this disease and lead to symptoms such as chronic knee pain, stiffness and restricted movement. For many patients, total knee replacement is ultimately the last resort. The Dutch orthopaedic startup ATRO Medical wants to create a solution for the years of pain that precedes a new knee.
The new meniscus prosthesis should serve as a new shock absorber in the knee, reducing bone-to-bone contact and reducing pain in the knee joint. A first version of this implant has been made for the inner meniscus. It is currently being tested in the first patients after ten years of research. However, there is still no solution for the outer meniscus. Forty percent of the complaints are related to problems with this outer meniscus.
The consortium of ATRO Medical, the Swiss company Samaplast and the Orthopaedic Research Laboratory (ORL) of the Radboudumc will receive €800,000 from EUROSTARS as a contribution to the total investment of €2 million to accelerate the development of this solution. Jan Hunik, CEO of Atro Medical: "The goal is to have this innovation ready for a clinical trial with patients within two years. Both the replacement of the worn out exterior meniscus by a wear-resistant plastic and the short development time of this project would be unique in the world of orthopaedics".
Consortium partner ORL of the Radboudumc has been involved in meniscus research as a biomechanical expert for many years and was already part of the team that wrote the first patents for meniscus replacement. Dennis Janssen, head of experimental research at ORL: "After the earlier successful development of the inner meniscus prosthesis, this EUROSTARS grant gives us the opportunity to apply our expertise to the outer meniscus as well. This project is therefore a nice and logical continuation of our joint work".
The Swiss partner Samaplast specialises in the manufacture of high quality and medical plastic products. Consortium leader ATRO Medical is a spin-off of the Radboudumc and DSM and focuses on the development of sustainable meniscus prostheses. Together, the parties have the expertise to quickly develop the new meniscus prosthesis with the EUROSTARS financing.
EUROSTARS supports international innovative projects led by R&D performing SMEs such as ATRO Medical. This EU programme aims to increase value creation within Europe, economic growth and employment.
ATRO Medical is a spin-off of DSM and Radboudumc with branches in Nijmegen and Oss (NL).
Related news items
Jong KNCV organizes a Pitch competition for PhD candidates13 August 2020
Are you a PhD candidate and would you like to win 500 euros with a pitch about your research? Young KNCV gives you that chance! During the KNCV Chemistry 2020 Evening on October 8th.read more
Collective invasion induced by autocrine purinergic loop through connexin-43 hemichannels13 August 2020
Peter Friedl and Paul Span show in Journal of Cell Biology that breastcancer cells release purines into the extracellular space via connexin-43 hemichannels to control collective invasion.read more
TP53 allelic state is critical for diagnostic and prognostic precision in blood cancer12 August 2020
An international study, in which Joop Jansen participated, shows that a double mutaton in TP53 gene deteriotes the prognosis of a rare form of blood cancer. If there is only one mutation or no mutation, then the prognosis is better.read more
BCG vaccine is safe with no increased risk of COVID-19 symptoms says Mihai Netea11 August 2020
The BCG vaccine has a general stimulatory effect on the immune system and is therefore effective against multiple infectious diseases - possibly also against COVID-19.read more
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
Increased role of patients after bowel cancer treatment30 July 2020
Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.read more